Regentis Receives IDE Approval for Pivotal GelrinC Clinical Trial
Regentis Biomaterials received FDAÂ Investigational Device Exemption approval to initiate a pivotal Phase III clinical study of its GelrinC procedure to treat focal knee cartilage defects. Sep 26, 2016